Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires cautious adoption and patient-centered decision-making in clinical practice.

A free community lecture by a national expert on schizophrenia treatment will be held from 8 a.m. to noon on Dec. 10 at Peak Vista Community Health Centers, 2828 International Circle, Suite 120, in ...

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies showed ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...

Current treatments for cognitive symptoms in patients with diagnoses such as schizophrenia are inadequate. We need to ...

Discover the future of schizophrenia research. Join CenExel experts Dr. David Walling and Dr. Lara Shirikjian as they explore ...

A new study has found that, contrary to expectations, pre-treatment with cannabidiol, or CBD, exacerbated the acute memory ...

For numerous individuals with schizophrenia, living with the condition involves challenges, not only related to ...

Panelists discuss how schizophrenia imposes significant economic costs across direct medical expenses, nonmedical expenses, and indirect costs, with negative symptoms particularly amplifying the ...

The invisible friends Cat Price talked about in childhood were chalked up to an active imagination, and her adolescent angst and hostility got interpreted as teenage rebellion. When, as a high school ...

A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Md. automation The U.S. Food and Drug Administration (FDA) on Thursday approved the first ...